Targeting the ErbB Family in Head and Neck Cancer

European Oncological Disease, 2007;1(2):35-40

Head and neck cancer is the sixth most common cancer, representing about 5% of all cancers. Each year, more than half a million new cases are diagnosed worldwide.1–3 Over the past decade, the important role of different growth factors and their receptors and signal transduction pathways in the genesis and progression of tumours has been well recognised, and their mechanism of action and interaction is gradually being unravelled.4–10 The ErbB family comprises four members: human epidermal growth factor receptor (EFGR; HER 1), HER2 (c-erb-B2), HER3 (cerb- B3) and HER4 (c-erb-B4).
Epidermal Growth Factor Receptor
EGFR and its ligand-transforming growth factor-alpha (TGF-α) are overexpressed in the vast majority of cases of squamous cell carcinoma of the head and neck (SCCHN). EGFR overexpression is an early event in carcinogenesis and steadily increases in parallel with histological abnormalities from hyperplasia, through carcinoma in situ to invasive carcinoma.11 EGFR overexpression is the result of an enhanced transcription or a gene amplification.12,13 There is a large body of evidence indicating that EGFR overexpression is a strong, independent and unfavourable prognostic factor for loco-regional control, disease-free survival and overall survival in SCCHN.14–21 Two of the potential EGFR-targeting strategies are currently in use. Monoclonal antibodies (MAbs) are directed at the extracellular domain of the receptor and at the small-molecule and adenosine tri-phosphate (ATP)-competitive tyrosine kinase inhibitors (TKIs) (see Table 1).22–29
Monoclonal Antibodies
MAbs targeting EGFR that are under clinical development include IMC225 (cetuximab), EMD-72000 (matuzumab), ABX-EGF (panitumumab), h-R3 (nimotuzumab), 2F8 (zalutumumab) and ICR62.22 The first MAb to enter the clinic was cetuximab (IMC225). Pre-clinically, it has antitumoral activity on its own and acts synergistically with chemotherapy and radiotherapy.25,26
Cetuximab
Cetuximab is a chimeric human/murine immunoglobulin IgG1 antibody that binds with higher affinity to the EGFR than the natural ligands EGF and tumour necrosis factor-alpha (TNF-α). The cetuximab-bound EGFR is internalised and degraded without receptor phosphorylation and activation. The availability of EGFR on the cell surface is reduced and the receptor downregulated. The most common side effects are fever, chills, asthenia, nausea, transaminase elevation and skin toxicity.25,26 A recently published large, multicentre, international phase III trial30 randomised 424 patients with stage III or IV non-metastatic squamous cell carcinoma of the oropharynx, hypopharynx or larynx to radiotherapy alone or to radiotherapy in combination with weekly cetuximab. There was a significant increase in the median duration of loco-regional control (24.4 versus 14.9 months; p=0.005) and the median duration of survival (49 versus 29.3 months; p=0.03). The only differences in grade 3/4 acute toxicity were acneiform rash and infusion reactions, which occurred in 17 and 3% of patients, respectively. In particular, the grade 3/4 radiationrelated mucosal toxicity was no worse in the cetuximab arm (54 versus 52%). The trial was conceived before the publication of a meta-analysis that clearly established the superiority of cisplatin-based chemoradiation over radiotherapy alone as definitive treatment for loco-regionally advanced SCCHN. Thus, the control arm used in the trial can no longer be considered the current standard of care for this population.
References:
  1. Ferlay J, Bray F, Pisani P, et al., GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide, IARC CancerBase, 2004, IARC Press.
  2. Jemal ZA, Tiwari RC, Murray T, et al., American Cancer Society, CA Cancer J Clin, 2004;54:8–29.
  3. Vermorken JB, Medical treatment in head and neck cancer, Ann Oncol, 2005;16:S258–64.
  4. Cohen S, The stimulation of epidermal proliferation by a specific protein (EGF), Dev Biol, 1965;12:394–407.
  5. Vermorken JB, Hitt R, Geoffrois L, et al., Cetuximab plus platinum-based therapy first-line in recurrent and/or metastatic squamous cell carcinoma of the head and nexk: efficacy and safety results of a randomized phase III trial (EXTREME), Eur J Cancer, 2007;43(Suppl. 4):abstract 5501.
  6. Hynes NE, Lane HA, ERBB receptors and cancer: the complexity of targeted inhibitors, Nat Rev Cancer, 2005;5:341–54.
  7. Pal SK, Pegram M, Epidermal Growth Factor Receptor and signal transduction: potential targets for anticancer therapy, Anticancer Drugs, 2005;16:483–94.
  8. Yarden Y, Sliwkowski MX, Untangling the ErbB signalling network, Nat Rev Cancer, 2001;2:127–37.
  9. Schlessinger J, Cell signalling by receptor tyrosine kinases, Cell, 2000;103:211–25.
  10. Zimmerman M, Zouhair A, Azria D, et al., The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications, Radiat Oncol, 2006;1:11.
  11. Grandis JR, Tweardy DJ, Elevated levels of transforming growth factor receptor-alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer, Cancer Res, 1993;53:3579–84.
  12. Chung CH, Ely K, L McGavran L, et al., Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas, J Clin Oncol, 2006;24:4,170–76.
  13. Mrhalova M, Plzak J, Betka J, et al., Epidermal growth factor receptor – its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas, Neoplasma, 2005;52:338–43.
  14. Nicholson RI, Gee JMW, Harper ME, EGFR and cancer prognosis, Eur J Cancer, 2001;37:S9–15.
  15. Demiral AN, Sarioglu S, Birlik B, et al., Prognostic significance of EGF receptor expression in early glottic cancer, Auris Nasus Larynx, 2004;31:417–24.
  16. Ang KK, Berkey BA, Tu X, et al., Impact of Epidermal Growth Factor Receptor Expression on survival and pattern of relapse in patients with advanced head and neck carcinoma, Cancer Res, 2002;62:7350–56.
  17. Grandis JR, Melhem MF, Gooding WE, et al., Levels of TGF and EGFR protein in head and neck squamous cell carcinoma and patient survival, J Natl Cancer Inst, 1998;90:824–32.
  18. Grandis JR, Prognostic biomarkers in head and neck cancer, Clin Cancer Res, 2006;2:5005–6.
  19. Dassonville O, Formento JL, Francoul M, et al., Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer, J Clin Oncol, 1993;11:1873–8.
  20. Maurizi M, Almadori G, Ferrandina G, et al., Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma, Br J Cancer, 1996;74:1253–7.
  21. Smid EJ, Stoter TR, Bloemena E, et al., The importance of immunohistochemical expression of EGFR in squamous cell carcinoma of the oral cavity treated with surgery and postoperative radiotherapy, Int J Radiat Oncol Biol Phys, 2006;65:1323–9.
  22. Specenier P, Vermorken JB, Targeted therapies in head and neck cancer, Targ Oncol, 2007;2:73–88.
  23. Cruz JJ, Ocana A, Del Barco E, Pandiella A, Targeting tyrosine kinases and their signal transduction routes in head and neck cancer, Ann Oncol, 2007;18:421–30.
  24. El-Rayes BF, LoRusso PM, Targeting the epidermal growth factor receptor, Br J Cancer, 2004;91:418–24.
  25. Marshall L, Clinical implications of the mechanism of Epidermal Growth Factor Receptor Inhibitors, Cancer, 2006;107:1207–18.
  26. Modjtahedi H, Molecular therapy of head and neck cancer, Cancer Metastasis Rev, 2006;24:129–45.
  27. Choong NW, Cohen EEW, Epidermal growth factor receptordirected therapy in head and neck cancer, Crit Rev Oncol Hematol, 2006;57:25–43.
  28. Baselga J, Artega CL, Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer, J Clin Oncol, 2005;23:2445–59.
  29. Cohen EEW, Role of epidermal growth factor receptor pathwaytargeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck, J Clin Oncol, 2006;24:2659–65.
  30. Bonner JA, Harrari P, Giralt J, et al., Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck, N Engl J Med, 2006;354:567–78.
  31. Pfister DG, Su YB, Kraus DH, et al., Concurrent cetuximab, cisplatin and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm, J Clin Oncol, 2006;24:1072–8.
  32. Kies MS, Garden AS, Holsinger C, et al., Induction chemotherapy with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck, J Clin Oncol, 2006;24: abstract 520.
  33. Burtness B, Goldwasser M, Flood W, et al., Phase III randomised trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Co-operative Oncology Group Study, J Clin Oncol, 2005;23:8646–54.
  34. Bourhis J, Rivera F, Mesia R, et al., Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck, J Clin Oncol, 2006;24:2866–72.
  35. Vermorken JB, Mesia R, Vega-Villegas ME, et al., Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) (EXTREME), J Clin Oncol, 2006;24: abstract 5537.
  36. Baselga J, Trigo JM, Bourhis J, et al., Phase II multicentre study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck, J Clin Oncol, 2005;24:5568–77.
  37. Herbst RS, Arquette M, Shin DM, et al., Phase II multicentre study of the epidermal growth factor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck, J Clin Oncol, 2005;23:5578–87.
  38. Vermorken JB, Trigo J, Hitt R, et al., Open-label, uncontrolled, multicentre phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy, J Clin Oncol, 2007;25:2171–7.
  39. Leon X, Hitt R, Constenla M, et al., A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinumbased chemotherapy, Clin Oncol, 2005;17:418–24.
  40. Vermorken J, Bourhis J, Trigo J, et al., Cetuximab (Erbitux®) in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies, J Clin Oncol, 2005;23: abstract 5505.
  41. Bier H, Hoffman T, Hauser U, et al., Clinical trial with escalating doses of the antiepidermal growth factor receptor humanised monoclonal antibody EMD72000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx, Cancer Chemother Pharmacol, 2001;47:519–24.
  42. Vanhoefer U, Tewes M, Rojo F, et al., Phase I study of the humanised Anti-EGFR Monoconal Antibody EMD72000 in patients with advanced solid tumours that express the Epidermal Growth Factor receptor, J Clin Oncol, 2004;22:175–84.
  43. Salazar R, Tabarnero J, Rojo F, et al., Dose-dependent inhibition of the EGFR and signalling pathways with the EGFR monoclonal antibody EMD 72000 administered every three weeks. A phase I pharmacokinetic/pharmacodynamic study to define the optimal biological dose, J Clin Oncol, 2004;22: abstract 2002.
  44. Foon KA, Yang XD, Weiner LM, et al., Pre-clinical and clinical evaluations of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, Int J Radiat Oncol Biol Phys, 2004;58: 984–90.
  45. Winquist E, Nabid A, Sicheri D, et al., A phase I dose escalation study of a humanised monoclonal antibody to EGFR (hR3) in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) treated with radiotherapy (RT), J Clin Oncol, 2002;21: abstract 926.
  46. Crombet T, Osorio M, Cruz T, et al., Use of the humanised Anita- EGFR Monoclonal Antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients, J Clin Oncol, 2004;22:1646–54.
  47. Bastholt L, Specht L, Jensen K, et al., A novel fully human monoclonal antibody against epidermal growth factor receptor (EGFR). First clinical and FDG-PET imaging results from a phase I/II trial conducted by the Danish Head and Neck Cancer Study Group (DAHANCA) in patients with squamous cell carcinoma of the head and neck (SCCHN), J Clin Oncol, 2004;23: abstract 5530.
  48. Modjtahedi H, Hickish T, Nicolson M, et al., Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer, Br J Cancer, 1996;73:228–35.
  49. Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, et al., Dual mode of action of a Human Anti-EGFR Monoclonal Antibody for cancer therapy, J Immun, 2004;173:4699–4707.
  50. Curnow RT, Clinical experience with CD-64-directed immunotherapy. An overview, Cancer Immunol Immunother, 1997;45:181–94.
  51. Cohen EEW, Rosen F, Stadler WM, et al., Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck, J Clin Oncol, 2003;21:1980–77.
  52. Kirby AM, A’Hern RP, D’Ambrosio C, et al., Gefitinib (ZD1839, Iressa®) as palliative treatment in recurrent or metastatic head and neck cancer, Br J Cancer, 2006;94:631–6.
  53. Wheeler RH, Jones D, Sharma P, et al., Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck, J Clin Oncol, 2005;23: abstract 5531.
  54. Cohen EEW, Kane MA, List MA, et al., Phase II trial of gefitinib 250mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck, Clin Cancer Res, 2005;11:8418–24.
  55. Stewart JSW, Cohen EEW, Licitra L, et al., A phase III randomised parallel-group study of gefitinib (IRESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck, Proc Am Assoc Cancer Res, 2007; abstract 3522.
  56. Soulieres D, Senzer NN, Vokes EE, et al., Multicentre phase II study of erlotinib, an oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck, J Clin Oncol, 2004;22:77–85.
  57. Herbst RS, Prager D, Hermann R, et al., TRIBUTE: a phase III trial of Erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer, J Clin Oncol, 2005;23:5892–9.
  58. Giaccone G, Herbst RS, Manegold C, et al., Gefitinib in Combination with Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial – INTACT 1, J Clin Oncol, 2004;22:777–84.
  59. Herbst RS, Giaccone G, Schiller JH, et al., Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer, J Clin Oncol, 2004;22:785–94.
  60. Magne N, Fischel JL, Dubreuil A, et al., Sequence-dependent effects of ZD1839 (Iressa®) in combination with cytotoxic treatment in human head and neck cancer, Br J Cancer, 2002;86: 819–27.
  61. Choe MS, Chen Z, Zhang X, et al., Sequence-dependent effect of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFRTKI), ZD1839 or Iressa in combination with docetaxel and cisplatin in squamous cell carcinoma of the head and neck (SCCHN), Proc Am Assoc Cancer Res, 2005; abstract 1396.
  62. Mukesh K, Nyati MN, Chun PY, et al., Optimum scheduling for better therapeutic outcome is required for Gefitinib and Gemcitabine treatment for Head and Neck cancer, Proc Am Assoc Cancer Res, 2005; abstract 122.
  63. Cohen EE, Harad DJ, Stenson KM, et al., Integration of Gefitinib (G), into a Concurrent Chemoradiation (CRT) Regimen Followed by Adjuvant Therapy in Patients with Locally Advanced Head and Neck Cancer (HNC) – a Phase II Trial, J Clin Oncol, 2005;23: abstract 5506.
  64. Doss HH, Greco FA, Meluch AA, et al., Induction chemotherapy + gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck: A phase I/II trial of the Minnie Pearl Cancer Research Network, J Clin Oncol, 2006;24: abstract 5543.
  65. Savvides P, Agarwala SS, Greskovich J, et al., Phase I study of the EGFR tyrosine kinase inhibitor erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN), J Clin Oncol, 2006;24: abstract 5545.
  66. Herchenhorn D, Dias FL, Ferreira CG, et al., Phase I/II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN), J Clin Oncol, 2006;24: abstract 5575.
  67. Rhoades CA, Kraut E, Schuller D, et al., Phase I and II study of OSI-774 and docetaxel in squamous cell carcinoma of the head and neck (SCCHN), J Clin Oncol, 2006;22: abstract 5541.
  68. Delord J, Thomas F, Benlyazid A, et al., Neo-adjuvant treatment with erlotinib in squamous cell carcinoma head and neck (SCCHN) patients before surgery provides an opportunity to find predictive factors of response, J Clin Oncol, 2006;24: abstract 5513.
  69. Huang S, Armstrong EA, Benavente S, et al., Dual-agent molecular targeting of the Epidermal Growth Factor Receptor (EGFR): combining Anti-EGFR antibody with Tyrosine Kinase Inhibitor, Cancer Res, 2004;64:5355–62.
  70. Matar P, Rojo F, Cassia R, et al., Combined Epidermal Growth Factor Receptor-targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC- 225); superiority over single-agent receptor targeting, Clin Cancer Res, 2004;10:6487–6501.
  71. Lal A, Glazer CA, Martinson HM, et al., Mutant epidermal growth factor receptor up-regulates molecular effectors of tumour invasion, Cancer Res, 2002;62:3335–9.
  72. Li B, Yuan M, Kim I-A, et al., Mutant epidermal growth factor receptor displays increased signalling through the phophatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin, Oncogene, 2002;23: 4594–4602.
  73. Lammering G, Valerie K, Lin PS, et al., Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance, Radiother Oncol, 2004;72:267–73.
  74. Sok JC, Coppelli FM, Thomas SM, et al., Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting, Clin Cancer Res, 2006;12:5064–73.
  75. Paez JG, Jänne PA, Lee JC, et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 2004;304:1497–1500.
  76. Lynch TJ, Bell DW, Sordella R, et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med, 2004;350: 2129–39.
  77. Jänne PA, Johnson BE, Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor kinase inhibitors, Clin Cancer Res, 2006;12: S4418–20.
  78. Inoue A, Suzuki T, Fukuhara T, et al., Prospective phase II study of gefitinib for chemotherapy-naïve patients with advanced nonsmall cell lung cancer with epidermal growth factor receptor gene mutations, J Clin Oncol, 2006;24:3340–46.
  79. Riely GJ, Pao W, Pham DK, et al., Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib, Clin Cancer Res, 2006;12:839–44.
  80. Uramato H, Sugio K, Oyama T, et al., Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in nonsmall cell lung cancer in Japanese, Lung Cancer, 2006;51:71–7.
  81. Pao W, Miller VA, Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions, J Clin Oncol, 2005;23: 2556–68.
  82. Eberhard DA, Johnson BE, Amler L, et al., Mutations in the Epidermal Growth Factor Receptor and in KRAS are predictive and prognostic indicators in patients with Non-Small Cell Lung Cancer treated with chemotherapy alone and in combination with erlotinib, J Clin Oncol, 2005;23:5900–09.
  83. Mukohara T, Engelman JA, Hanna N, et al., Differential effects of gefitinib and cetuximab on Non-Small Cell Lung Cancer cell lines bearing Epidermal Growth Factor Receptor mutation, J Natl Cancer Inst, 2005;97:1185–94.
  84. Guo M, Liu S, Herman JG, et al., Gefitinib-sensitising mutation in oesophageal carcinoma cell line Kyse 450, Cancer Biol Ther, 2006;5:152–5.
  85. Guo M, Liu S, Lu F, Gefitinib-sensitising mutations in oesophageal carcinoma, N Engl J Med, 2006;354:2193–4.
  86. Lee JW, Soung YH, Kim SY, et al., Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck, Clin Cancer Res, 2005;11:2879–82.
  87. Willmore-Payne C, Holden JA, Layfield LJ, Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck, Mod Pathol, 2006;19:634–40.
  88. Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, et al., Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma, Eur J Cancer, 2005;42:09–111.
  89. Cohen EEW, Lingen MW, Martin LE, et al., Response of some head and neck cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors may be linked to Mutation of ERBB2 rather than EGFR, Clin Cancer Res, 2005;11:8105–8.
  90. Mojica WD, Khoury T, Starostik PP, et al., Frequency of gefitinib responder mutations in EGFR (+) squamous cell carcinoma of the head and neck, Proc Am Assoc Cancer Res, 2005;992–3.
  91. Murray S, Linardou H, Razis E, et al., Screening for EGFR mutations in patients with head and neck cancer treated with gefitinib on a compassionate-use program: a Hellenic Cooperative Oncology Group study, Ann Oncol, 2006;17: abstract 578.
  92. Na I, Kang H, Park Y, et al., EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil, J Clin Oncol, 2006;24: abstract 10027.
  93. Xia W, Lau YK, Zhang HZ, et al., Combination of EGFR, HER- 2/neu, and HER3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members, Clin Cancer Res, 1999;5:4164–74.
  94. Gillison ML, Glisson BS, O’Leary E, et al., Phase II trial of trastuzumab (T), paclitaxel (P), and cisplatin© in metastatic (M) or recurrent(R) head and neck squamous cell carcinoma (HNSCC): response by tumour EGFR and HER2/neu status, J Clin Oncol, 2006;24:5511.
  95. Abidoye OO, Cohen EE, Wong SJ, et al., A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN), J Clin Oncol, 2006;24: abstract 5568.
  96. Bourhis J, Harrington K, Rosine D, et al., A phase I, open-label study (EGF100262) of lapatinib plus chemoradiation in patients with locally advanced squamous of carcinoma of the head and neck, Ann Oncol, 2006;17: abstract 576.
  97. Thomas GR, Nadiminti H, Regalado J, Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma, Int J Exp Pathol, 2005;86:347–63.
  98. Gallo O, Masini E, Bianchi B, et al., Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma, Hum Pathol, 2002;33:708–14.
  99. Peng J, Su C, Chang H, Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the hypopharynx, Hum Pathol, 2002;33:100–104.
  100. Lin D, Subbaramaiah K, Shah J, et al., Cyclo-oxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer, Head Neck, 2002;24:792–9.
  101. Itoh S, Matsui K, Furuta I, et al., Immunohistochemical study of overexpression of cyclooxygenase-2 in squamous cell carcinoma of the oral cavity: its importance as a prognostic predictor, Oral Oncol, 2003;39:829–35.
  102. Renkonen J, Wolff, Paavonen T, Expression of cyclooxygenase-2 in human tongue carcinoma and its precursor lesions, Virchows Arch, 2002;440:594–7.
  103. Pannone G, Bufo P, Caiaffa MF, et al., Cyclooxygenase-2 expression in oral squamous cell carcinoma, Int J Immunopathol Pharmacol, 2004;17:373–82.
  104. Chan G, Boyle JO, Yang EY, et al., Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck, Cancer Res, 1999;59:991–4.
  105. Grau JJ, Monzo JC, Palmero R, et al., Expression of cyclooxygenase-2 mRNA (COX2-mRNA) in peripheral blood of head and neck cancer patents and healthy controls, J Clin Oncol, 2004;22: abstract 5521.
  106. Lippman SM, Gibson N, Subbaramaiah K, et al., Combined targeting of the EGFR and cyclooxygenase-2 pathways, Clin Cancer Res, 2005;11:6097–9.
  107. Choe MS, Zhang X, JC Chin, et al., Interaction between epidermal growth factor receptor and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer, Mol Cancer Ther, 2005;4:1448–55.
  108. Chen Z, Zhang X, Li M, et al., Simultaneously targeting Epidermal Growth Factor Receptor, Tyrosine Kinase and Cyclooxygenase-2, an efficient approach to inhibition of Squamous Cell Carcinoma of the Head and Neck, Clin Cancer Res, 2004;10:5930–39.
  109. Zhang X, Chen ZG, Choe MS, et al., Tumour growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model, Clin Cancer Res, 2005;11:6261–9.
  110. Wirth LJ, Haddad RI, Lindeman NI, et al., Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck, J Clin Oncol, 2005;23:6976–81.
  111. Kyzas PA, Cunha IW, Ioannidis JPA, Prognostic significance of Vascular Endothelial Growth Factor Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma: A Meta- Analysis, Clin Cancer Res, 2005;11:1434–40.
  112. Mauer AM, Cohen EEW, Wong SJ, et al., Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, Bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN), J Clin Oncol, 2004;22: abstract 5539.
  113. Vokes EE, Cohen EE, Mauer AM, et al., A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck, J Clin Oncol, 2005;23: abstract 5504.
  114. Bozec A, Formento P, Fischel J-L, et al., Combined effect of EGFR-targeting with antiangiogenesis and irradiation, Proc Am Assoc Cancer Res, 2006; abstract 55.